Skip to main navigation
  • Contact
Aimmune
Menu CLOSE X
CLOSE X
  • About Aimmune
    • Company Overview
    • History
    • Leadership
    • Culture of Integrity
  • Our Product
    • Our Product
    • Expanded Access Policy
  • Our Pipeline
    • Our Pipeline
    • Our Focus
  • Media
    • Press Releases
  • Careers
    • Career Opportunities
  • Contact

Press Releases

Keyword Search

Recent News

March 13, 2020
Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability and Continued Immunomodulation After 18 and 24 Months of Treatment
February 27, 2020
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights
February 26, 2020
Aimmune Therapeutics to Present at Upcoming Investor Conferences
February 25, 2020
Aimmune to Present New Clinical Data at AAAAI Annual Meeting
February 20, 2020
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights
February 5, 2020
Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science
February 5, 2020
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
January 31, 2020
FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy
January 6, 2020
Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Current page 3

Media Contacts

Julie Normart
559-974-3245
jnormart@w2ogroup.com

Lauren Barbiero
646-564-2156
lbarbiero@w2ogroup.com

Email Alerts

About Aimmune
  • Company Overview
  • History
  • Leadership
  • Culture of Integrity
Our Product
  • Our Product
  • Expanded Access Policy
Our Pipeline
  • Our Pipeline
  • Our Focus
Media
  • Press Releases
Careers
  • Career Opportunities
© 2020 Aimmune Therapeutics. All rights reserved.
  •  
  • Terms of Use
  • Privacy Policy
  • Privacy Shield
  • Twitter Guidelines
  • Facebook Guidelines